Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4D1X

CDK2 in complex with Luciferin

4D1X の概要
エントリーDOI10.2210/pdb4d1x/pdb
関連するPDBエントリー4D1Z
分子名称CYCLIN-DEPENDENT KINASE 2, (4S)-2-(6-hydroxy-1,3-benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid (3 entities in total)
機能のキーワードtransferase, kinase
由来する生物種HOMO SAPIENS (HUMAN)
細胞内の位置Cytoplasm, cytoskeleton, microtubule organizing center, centrosome: P24941
タンパク質・核酸の鎖数1
化学式量合計34256.81
構造登録者
Rothweiler, U.,Engh, R.A. (登録日: 2014-05-05, 公開日: 2015-03-18, 最終更新日: 2023-12-20)
主引用文献Rothweiler, U.,Eriksson, J.,Stensen, W.,Leeson, F.,Engh, R.A.,Svendsen, J.S.
Luciferin and Derivatives as a Dyrk Selective Scaffold for the Design of Protein Kinase Inhibitors.
Eur.J.Med.Chem., 94:140-, 2015
Cited by
PubMed Abstract: D-Luciferin is widely used as a substrate in luciferase catalysed bioluminescence assays for in vitro studies. However, little is known about cross reactivity and potential interference of D-luciferin with other enzymes. We serendipitously found that firefly luciferin inhibited the CDK2/Cyclin A protein kinase. Inhibition profiling of D-luciferin over a 103-protein kinase panel showed significant inhibition of a small set of protein kinases, in particular the DYRK-family, but also other members of the CMGC-group, including ERK8 and CK2. Inhibition profiling on a 16-member focused library derived from D-luciferin confirms that D-luciferin represents a DYRK-selective chemotype of fragment-like molecular weight. Thus, observation of its inhibitory activity and the initial SAR information reported here promise to be useful for further design of protein kinase inhibitors with related scaffolds.
PubMed: 25768698
DOI: 10.1016/J.EJMECH.2015.02.035
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.1 Å)
構造検証レポート
Validation report summary of 4d1x
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon